NCT07104812

Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 15 (estimated)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and tolerability of 1 mg osilodrostat therapy in patients with mild autonomous cortisol secretion (MACS), and to determine the impact on 24h urine steroid metabolome and circadian cortisol/cortisone concentrations

Conditions

• Mild Autonomous Cortisol Secretion
• Autonomous Cortisol Secretion (ACS)

Interventions

Type	Name	Description
DRUG	Osilodrostat 1 MG	Osilodrostat 1 mg administered between noon and 6 pm daily, for 4 weeks

Timeline

• Start date: 2026-01-14
• Primary completion: 2027-01-01
• Completion: 2027-01-01
• First posted: 2025-08-05
• Last updated: 2026-02-11

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study